Rifapentine

BreastfeedingPediatric
  • TRADE NAME: Priftin (Sanofi-Aventis)
  • INDICATIONS: Tuberculosis (in combination with one or more antituberculosis drugs)
  • CLASS: Antibiotic, rifamycin
  • HALF-LIFE: 14–17 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Abiraterone, Alfentanil, Amiodarone, Angiotensin II receptor blockers, Anisindione, Antiarrhythmics, Anticoagulants, Antifungals, Aprepitant, Atovaquone, Barbiturates, Bedaquiline, Benzodiazepines, Beta blockers, Bictegravir/Emtricitabine/Tenofovir Alafenamide, Buspirone, Cabozantinib, Calcium channel blockers, Clopidogrel, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Corticosteroids, Cyclosporine, CYP2C8 substrates, CYP2C9 substrates, CYP3A4 substrates, Dapsone, Delavirdine, Dicumarol, Disopyramide, Dronedarone, Emtricitabine/Rilpivirine/Tenofovir Alafenamide, Enzalutamide, Erlotinib, Etravirine, Everolimus, Exemestane, Fentanyl, Flibanserin, Fluconazole, Food, Gefitinib, Guanfacine, Hormonal contraceptives, Imatinib, Indinavir, Isoniazid, Ixabepilone, Ledipasvir & Sofosbuvir, Maraviroc, Methadone, Mifepristone, Morphine, Mycophenolate, Mycophenolate, Nilotinib, Pazopanib, Phenytoin, Praziquantel, Propafenone, Protease inhibitors, Quinidine, Ramelteon, Ranolazine, Repaglinide, Reverse transcriptase inhibitors, Rilpivirine, Ritonavir, Romidepsin, Saxagliptin, Simeprevir, Sofosbuvir, Sofosbuvir & Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Solifenacin, Sorafenib, Sunitinib, Tacrolimus, Tadalafil, Tamoxifen, Temsirolimus, Tenofovir Alafenamide, Terbinafine, Tolvaptan, Treprostinil, Ulipristal, Vandetanib, Vemurafenib, Vitamin K antagonists, Voriconazole, Warfarin, Zaleplon, Zidovudine, Zolpidem

PREGNANCY CATEGORY: C

Our database has 65 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OCULAR
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric